Literature DB >> 21266362

Hydrophilic agarose macrobead cultures select for outgrowth of carcinoma cell populations that can restrict tumor growth.

Barry H Smith1, Lawrence S Gazda, Bryan L Conn, Kanti Jain, Shirin Asina, Daniel M Levine, Thomas S Parker, Melissa A Laramore, Prithy C Martis, Horatiu V Vinerean, Eric M David, Suizhen Qiu, Alison J North, C Guillermo Couto, Gerald S Post, David J Waters, Carlos Cordon-Cardo, Richard D Hall, Bruce R Gordon, Carolyn H Diehl, Kurt H Stenzel, Albert L Rubin.   

Abstract

Cancer cells and their associated tumors have long been considered to exhibit unregulated proliferation or growth. However, a substantial body of evidence indicates that tumor growth is subject to both positive and negative regulatory controls. Here, we describe a novel property of tumor growth regulation that is neither species nor tumor-type specific. This property, functionally a type of feedback control, is triggered by the encapsulation of neoplastic cells in a growth-restricting hydrogel composed of an agarose matrix with a second coating of agarose to form 6- to 8-mm diameter macrobeads. In a mouse cell model of renal adenocarcinoma (RENCA cells), this process resulted in selection for a stem cell-like subpopulation which together with at least one other cell subpopulation drove colony formation in the macrobeads. Cells in these colonies produced diffusible substances that markedly inhibited in vitro and in vivo proliferation of epithelial-derived tumor cells outside the macrobeads. RENCA cells in monolayer culture that were exposed to RENCA macrobead-conditioned media exhibited cell-cycle accumulation in S phase due to activation of a G(2)/M checkpoint. At least 10 proteins with known tumor suppression functions were identified by analysis of RENCA macrobead-conditioned media, the properties of which offer opportunities to further dissect the molecular basis for tumor growth control. More generally, macrobead culture may permit the isolation of cancer stem cells and other cells of the stem cell niche, perhaps providing strategies to define more effective biologically based clinical approaches to treat neoplastic disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21266362     DOI: 10.1158/0008-5472.CAN-10-2258

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Treatment of agarose-agarose RENCA macrobeads with docetaxel selects for OCT4(+) cells with tumor-initiating capability.

Authors:  Lawrence S Gazda; Prithy C Martis; Melissa A Laramore; Melissa A Bautista; Atira Dudley; Horatiu V Vinerean; Barry H Smith
Journal:  Cancer Biol Ther       Date:  2013-09-12       Impact factor: 4.742

2.  Development of polymer based cryogel matrix for transportation and storage of mammalian cells.

Authors:  Jyoti Kumari; Ashok Kumar
Journal:  Sci Rep       Date:  2017-01-31       Impact factor: 4.379

Review 3.  Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.

Authors:  Inés Mármol; Cristina Sánchez-de-Diego; Alberto Pradilla Dieste; Elena Cerrada; María Jesús Rodriguez Yoldi
Journal:  Int J Mol Sci       Date:  2017-01-19       Impact factor: 5.923

4.  MEF2 plays a significant role in the tumor inhibitory mechanism of encapsulated RENCA cells via EGF receptor signaling in target tumor cells.

Authors:  Prithy C Martis; Atira T Dudley; Melissa A Bemrose; Hunter L Gazda; Barry H Smith; Lawrence S Gazda
Journal:  BMC Cancer       Date:  2018-12-04       Impact factor: 4.430

5.  CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells.

Authors:  Caterina Ieranò; Crescenzo D'Alterio; Simona Giarra; Maria Napolitano; Giuseppina Rea; Luigi Portella; Assunta Santagata; Anna Maria Trotta; Antonio Barbieri; Virginia Campani; Antonio Luciano; Claudio Arra; Anna Maria Anniciello; Gerardo Botti; Laura Mayol; Giuseppe De Rosa; Roberto Pacelli; Stefania Scala
Journal:  Cell Death Dis       Date:  2019-07-22       Impact factor: 8.469

6.  Clinical laboratory and imaging evidence for effectiveness of agarose-agarose macrobeads containing stem-like cells derived from a mouse renal adenocarcinoma cell population (RMBs) in treatment-resistant, advanced metastatic colorectal cancer: Evaluation of a biological-systems approach to cancer therapy (U.S. FDA IND-BB 10091; NCT 02046174, NCT 01053013).

Authors:  Barry H Smith; Lawrence S Gazda; Thomas J Fahey; Angelica Nazarian; Melissa A Laramore; Prithy Martis; Zoe P Andrada; Joanne Thomas; Tapan Parikh; Sudipta Sureshbabu; Nathaniel Berman; Allyson J Ocean; Richard D Hall; David J Wolf
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

7.  Anti-proliferative and anti-tumour effects of lymphocyte-derived microparticles are neither species- nor tumour-type specific.

Authors:  Chun Yang; Wei Xiong; Qian Qiu; Houda Tahiri; Rosanne Superstein; Anne-Sophie Carret; Przemyslaw Sapieha; Pierre Hardy
Journal:  J Extracell Vesicles       Date:  2014-05-09

8.  No evidence of viral transmission following long-term implantation of agarose encapsulated porcine islets in diabetic dogs.

Authors:  Lawrence S Gazda; Horatiu V Vinerean; Melissa A Laramore; Richard D Hall; Joseph W Carraway; Barry H Smith
Journal:  J Diabetes Res       Date:  2014-06-05       Impact factor: 4.011

9.  First-in-Human Phase 1 Trial of Agarose Beads Containing Murine RENCA Cells in Advanced Solid Tumors.

Authors:  Barry H Smith; Tapan Parikh; Zoe P Andrada; Thomas J Fahey; Nathaniel Berman; Madeline Wiles; Angelica Nazarian; Joanne Thomas; Anna Arreglado; Eugene Akahoho; David J Wolf; Daniel M Levine; Thomas S Parker; Lawrence S Gazda; Allyson J Ocean
Journal:  Cancer Growth Metastasis       Date:  2016-08-02

Review 10.  Gold (III) Derivatives in Colon Cancer Treatment.

Authors:  Agata Gurba; Przemysław Taciak; Mariusz Sacharczuk; Izabela Młynarczuk-Biały; Magdalena Bujalska-Zadrożny; Jakub Fichna
Journal:  Int J Mol Sci       Date:  2022-01-10       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.